tbuckley/cabot-search huggingface dataset:
IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).
Authors: Michael B. Atkins, David F. McDermott, Thomas Powles, Robert J. Motzer, Brian I. Rini, Lawrence Fong, Richard Wayne Joseph, Sumanta K. Pal, Mario Sznol, John D. Hainsworth, Walter Michael Stadler, Thomas E. Hutson, Alain Ravaud, Sergio Bracarda, Cristina Suarez, Toni K. Choueiri, Jiaheng Qiu, Mahrukh A. Huseni, Christina Schiff, Bernard J. Escudier
Journal: Journal of Clinical Oncology (2017)

4505 Background: While inhibiting VEGF improves outcomes in mRCC pts, most develop resistance, often within a year. Here, we report results from a Ph II study of atezo (anti–PD-L1) and bev (anti-VEGF) vs and following atezo or sun (TKI) in mRCC pts. Methods: Pts with untreated mRCC were enrolled in the hypothesis generating IMmotion150 study (NCT01984242) and randomized to atezo 1200 mg IV q3w + bev 15 mg/kg IV q3w, atezo alone or sun 50 mg PO QD 4 wk on/2 wk off. After progression on atezo or sun, crossover to atezo + bev was allowed. PD-L1 status was scored on tumor-infiltrating immune cells (IC, SP142 IHC assay). The primary analysis was modified prior to final analysis to reflect the coprimary endpoints of IRF-assessed PFS (RECIST v1.1) in ITT pts and pts with PD-L1 expression on ≥ 1% of IC (PD-L1+). Results: 54% of pts were PD-L1+. In PD-L1+ pts 1L treatment resulted in a PFS hazard ratio (HR) of 0.64 for atezo + bev vs sun (table). After 1L treatment, 78% of sun and 60% of atezo pts who progressed subsequently received atezo + bev and achieved ORRs of 28% and 24%, respectively (table). Safety was comparable to the known individual profiles of atezo and bev. Additional clinical, safety and biomarker data will be presented. Conclusions: Atezo + bev resulted in encouraging antitumor activity in 1L pts with PD-L1+ mRCC. Preliminary activity in the 2L setting was demonstrated in pts who crossed over to atezo + bev, regardless of prior therapy. 1L atezo + bev vs sun is being evaluated in the ongoing Ph III study IMmotion151 (NCT02420821). Clinical trial information: NCT01984242. [Table: see text]
Estimated risk reduction of mortality and transplantation with bezafibrate in patients with PBC and inadequate response to UDCA: application of the UK-PBC and Global PBC risk scores to the BEZURSO trial
Authors: C. Corpechot, A. Rousseau, O. Chazouillères, L.G. Antonia, F. Habersetzer, P. Mathurin, O. Goria, P. Pascal, A.M. Franza, C. Silvain, A. Abergel, M.D. Gratien, D. Larrey, R. Olivier, J.-P. Bronowicki, J. Boursier, V. De Ledinghen, A. Heurgue-Berlot, E. Nguyen-Khac, F. Zoulim, O.-H. Isabelle, J.-P. Zarski, N. Gisèle, G. Farid, F.-H. Admane, T. Simon, R. Poupon
Journal: Journal of Hepatology (2018)
Real world experience of retreatment of chronic hepatitis C patients who failed IFN-free DAA therapy
Authors: K. Kozbial, R. Al-Zoairy, B. Schaefer, M. Gschwantler, R.E. Stauber, S. Hametner, A. Maieron, H. Laferl, M. Strasser, A. Hayat-Khayyati, C. Datz, L. Kramer, I. Graziadei, A. Stättermayer, S. Beinhardt, P. Munda, H. Zoller, M. Trauner, H. Hofer, P. Ferenci
Journal: Journal of Hepatology (2018)
High-Discrimination Factor Nanosensor Based on Tetrahedral DNA Nanostructures and Gold Nanoparticles for Detection of MiRNA-21 in Live Cells
Authors: Shulian Bai, Bangtian Xu, Yongcan Guo, Juhui Qiu, Wen Yu, Guoming Xie
Journal: Theranostics (2018)

While detection of microRNA with or without signal amplification is highly informative, nanosensors with high specificity for cell-specific RNA detection are rare.Methods: In this study, a tetrahedral DNA nanostructure (TDN) with a specific function was combined with gold nanoparticles (Au-NP) possessing fluorescence quenching effects and a large surface area to fabricate a fluorescence resonance energy transfer based nanosensor (Au-TDNN).The presence of miR-21 (target) can separate the fluorescent dye-labeled detection probe on Au-TDNNs from Au-NPs, which separates the donor and acceptor, thus inducing an intensive fluorescence signal.High specificity for discerning point mutation targets was achieved by rationally designing the nucleic acid strand displacement reaction to occur spontaneously with ΔG 0 ≈ 0 based on thermodynamic parameters; under this condition, slight thermodynamic changes caused by base mismatch exert significant effects on hybridization yield.Results: Chemically synthesized DNA of three single-base-changed analogues of target, let-7d, and miR-200b were tested.A discrimination factor (DF) of 15.4 was produced by the expected detection probe on Au-NPs for proximal single-base mismatch.As the control group, the DF produced by an ordinary detection probe on Au-NPs only reached 2.4.The feasibility of the proposed strategy was also confirmed using hepatocyte cancer cells (HepG2).Conclusion: This improved nanosensor opens a new avenue for the specific and easy detection of microRNA in live cells.
Effects of empathic and positive communication in healthcare consultations: a systematic review and meta-analysis
Authors: Jeremy Howick, Andrew Moscrop, Alexander Mebius, Thomas R Fanshawe, George Lewith, Felicity L Bishop, Patriek Mistiaen, Nia W Roberts, Eglė Dieninytė, Xiao-Yang Hu, Paul Aveyard, Igho J Onakpoya
Journal: Journal of the Royal Society of Medicine (2018)

Background Practitioners who enhance how they express empathy and create positive expectations of benefit could improve patient outcomes. However, the evidence in this area has not been recently synthesised. Objective To estimate the effects of empathy and expectations interventions for any clinical condition. Design Systematic review and meta-analysis of randomised trials. Data sources Six databases from inception to August 2017. Study selection Randomised trials of empathy or expectations interventions in any clinical setting with patients aged 12 years or older. Review methods Two reviewers independently screened citations, extracted data, assessed risk of bias and graded quality of evidence using GRADE. Random effects model was used for meta-analysis. Results We identified 28 eligible (n = 6017). In seven trials, empathic consultations improved pain, anxiety and satisfaction by a small amount (standardised mean difference −0.18 [95% confidence interval −0.32 to −0.03]). Twenty-two trials tested the effects of positive expectations. Eighteen of these (n = 2014) reported psychological outcomes (mostly pain) and showed a modest benefit (standardised mean difference −0.43 [95% confidence interval −0.65 to −0.21]); 11 (n = 1790) reported physical outcomes (including bronchial function/ length of hospital stay) and showed a small benefit (standardised mean difference −0.18 [95% confidence interval −0.32 to −0.05]). Within 11 trials (n = 2706) assessing harms, there was no evidence of adverse effects (odds ratio 1.04; 95% confidence interval 0.67 to 1.63). The risk of bias was low. The main limitations were difficulties in blinding and high heterogeneity for some comparisons. Conclusions Greater practitioner empathy or communication of positive messages can have small patient benefits for a range of clinical conditions, especially pain. Protocol registration Cochrane Database of Systematic Reviews (protocol) DOI: 10.1002/14651858.CD011934.pub2.
Characterization of systemic inflammatory response in hepatorenal syndrome in cirrhosis. A major role for il-6, TNF-alpha, and VCAM
Authors: C. Sole, E. Solà, M. Morales-Ruiz, P. Huelin, M. Carol, R. Moreira, I. Graupera, E. Pose, L. Napoleone, G. De Prada, X. Ariza, A. Juanola, N. Fabrellas, W. Jiménez, P. Ginès
Journal: Journal of Hepatology (2018)
Low density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial Hypercholesterolemia modelling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection
Authors: Jérôme Caron, Véronique Péne, L. Tolosa, M. Villaret, E. Luce, Angélique Fourrier, S. Sami, E. Bruckert, María José Gómez-Lechón, T.H. Nguyen, A.R. Rosenberg, A. Weber, A. Dubart-Kupperschmitt
Journal: Journal of Hepatology (2018)
Mixed hepatic iron deposition but not serum ferritin is associated with the presence of nonalcoholic steatohepatitis (NASH)
Authors: E. Buzzetti, S. Petta, R. Manuguerra, D. Cabibi, T.V. Luong, E. Corradini, M. Pinzani, A. Craxi, A. Pietrangelo, E. Tsochatzis
Journal: Journal of Hepatology (2018)
The My Child Matters programme: effect of public–private partnerships on paediatric cancer care in low-income and middle-income countries
Authors: Scott C Howard, Alia Zaidi, Xueyuan Cao, Olivier Weil, Pierre Bey, Catherine Patte, Angelica Samudio, Laurie Haddad, Catherine G Lam, Claude Moreira, Augusto Pereira, Mhamed Harif, Laila Hessissen, Salma Choudhury, Ligia Fu, Miguela A Caniza, Julius Lecciones, Fousseyni Traore, Raul C Ribeiro, Anne Gagnepain-Lacheteau
Journal: The Lancet Oncology (2018)
Influence of statines in the modifications of lipid and hydrocarboned metabolism in patients with chronic hepatitis C treated with direct-acting antivirals
Authors: P. Linares, B. Álvarez-Cuenllas, F. Jorquera, R. Quinones, N. Reyes, G. Molina, C. Villar, M. Guerra-González, E. Fernández-Moran, E. Gutiérrez-Gutiérrez, D. Fierro-González
Journal: Journal of Hepatology (2018)
TCTAP A-001 Treatment of Coronary DES Restenosis with a Sirolimus or Paclitaxel Coated Balloon
Authors: Rosli Mohd Ali, Muhamad Ali SK Abdul Kader, Wan Azman Wan Ahmad, Tiong Kiam Ong, Houng Bang Liew, Bruno Scheller
Journal: Journal of the American College of Cardiology (2018)
Biomarkers of immune checkpoint inhibitor response in metastatic breast cancer: PD-L1 protein expression, <i>CD274</i> gene amplification, and total mutational burden.
Authors: Jeffrey S. Ross, Laurie M Gay, Christine E. Sheehan, Siddhartha Dalvi, Olga Voronel, Julia Andrea Elvin, James Suh, Jo-Anne Vergilio, Garrett Michael Frampton, David Fabrizio, Zachary Rockow Chalmers, Saranya Chumsri, Siraj Mahamed Ali, Vincent A. Miller, Philip J. Stephens
Journal: Journal of Clinical Oncology (2016)

3057 Background: Predictive biomarkers for immune checkpoint inhibitors, such as PD-L1 (CD274) copy number, PD-L1 expression and tumor mutational burden (TMB), have not been widely studied in metastatic breast cancer (mBC). Methods: FFPE samples from 84 cases of BC, 71 ductal (IDC) and 13 lobular (ILC), were immunostained (IHC) using rabbit monoclonal PD-L1/CD274 (SP142). Membranous PD-L1 staining was scored as negative, low positive (1 – 24%) and high positive ( = or > 25%) for both tumor cells and tumor infiltrating lymphocytes (TILs). Comprehensive genomic profiling (CGP) was used to measure PD-L1gene amplification and total TMB, calculated by counting mutations across a 1.25Mb region spanning 315 genes. TMB was also calculated for a separate cohort of 6,751 metastatic BC (mBC). Results: PD-L1 immunoreactivity was noted as low positive in 4/84 (5%) BC [2 tumor+/TIL+ and 2 tumor+/TIL-], and as low positive in the TIL component for 5 (6%) additional BC [tumor-/TIL+]; all 9 (100%) were IDCs. No PD-L1 immunoreactivity was noted in the TIL component of the remaining cases, despite the presence of prominent TILs in most cases. PD-L1 protein expression correlated with decreased overall survival (OS) [100% PD-L1+ cases and 0% tumor-/TIL+ cases expired, (p = 0.002)], while showing a trend toward correlation with tumors that did not recur [100% PD-L1+ cases and 100% tumor-/TIL+ did not recur, (p = 0.08)] and age at diagnosis in the ER+ subgroup [100% PD-L1+ cases diagnosed at a peri-menopausal age and 100% tumor-/TIL+ cases diagnosed at a post-menopausal age, (p = 0.069)]. On multivariate analysis, tumor grade (p = 0.025) and disease recurrence independently predicted OS. PD-L1gene amplification was identified in only 57 (0.1%) of 6,751 mBC. High TMB, defined as greater than the top quartile across all indications, was found in 1,351 of 6,643 (20%) mBC cases. Conclusions: PD-L1 expression is found in both cancer cells and TILs and is a significant adverse prognostic factor in BC. PD-L1 amplification is extremely uncommon, whereas high TMB was found in 20% of mBC. The potential for these biomarkers to identify BC patients as candidates for immunotherapy warrants further study.
Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial
Authors: Hironori Ishigami, Yoshiyuki Fujiwara, Ryoji Fukushima, Atsushi Nashimoto, Hiroshi Yabusaki, Motohiro Imano, Haruhiko Imamoto, Yasuhiro Kodera, Yoshikazu Uenosono, Kenji Amagai, Shigenori Kadowaki, Hiroto Miwa, Hironori Yamaguchi, Takuhiro Yamaguchi, Tempei Miyaji, Joji Kitayama
Journal: Journal of Clinical Oncology (2018)

Purpose Intraperitoneal paclitaxel plus systemic chemotherapy demonstrated promising clinical effects in patients with gastric cancer with peritoneal metastasis. We aimed to verify its superiority over standard systemic chemotherapy in overall survival. Patients and Methods This randomized phase III trial enrolled patients with gastric cancer with peritoneal metastasis who had received no or short-term (&lt; 2 months) chemotherapy. Patients were randomly assigned at a two-to-one ratio to receive intraperitoneal and intravenous paclitaxel plus S-1 (IP; intraperitoneal paclitaxel 20 mg/m 2 and intravenous paclitaxel 50 mg/m 2 on days 1 and 8 plus S-1 80 mg/m 2 per day on days 1 to 14 for a 3-week cycle) or S-1 plus cisplatin (SP; S-1 80 mg/m 2 per day on days 1 to 21 plus cisplatin 60 mg/m 2 on day 8 for a 5-week cycle), stratified by center, previous chemotherapy, and extent of peritoneal metastasis. The primary end point was overall survival. Secondary end points were response rate, 3-year overall survival rate, and safety. Results We enrolled 183 patients and performed efficacy analyses in 164 eligible patients. Baseline characteristics were balanced between the arms, except that patients in the IP arm had significantly more ascites. The median survival times for the IP and SP arms were 17.7 and 15.2 months, respectively (hazard ratio, 0.72; 95% CI, 0.49 to 1.04; stratified log-rank P = .080). In the sensitivity analysis adjusted for baseline ascites, the hazard ratio was 0.59 (95% CI, 0.39 to 0.87; P = .008). The 3-year overall survival rate was 21.9% (95% CI, 14.9% to 29.9%) in the IP arm and 6.0% (95% CI, 1.6% to 14.9%) in the SP arm. Both regimens were well tolerated. Conclusion This trial failed to show statistical superiority of intraperitoneal paclitaxel plus systemic chemotherapy. However, the exploratory analyses suggested possible clinical benefits of intraperitoneal paclitaxel for gastric cancer.
Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial
Authors: Daniel M Blumberger, Fidel Vila-Rodriguez, Kevin E Thorpe, Kfir Feffer, Yoshihiro Noda, Peter Giacobbe, Yuliya Knyahnytska, Sidney H Kennedy, Raymond W Lam, Zafiris J Daskalakis, Jonathan Downar
Journal: The Lancet (2018)
Cerebrovascular Events After Cardiovascular Procedures
Authors: Jasneet K. Devgun, Sajjad Gul, Divyanshu Mohananey, Brandon M. Jones, M. Shazam Hussain, Yash Jobanputra, Arnav Kumar, Lars G. Svensson, E. Murat Tuzcu, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2018)
Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine
Authors: Siang-Boon Koh, Yann Wallez, Charles R. Dunlop, Sandra Bernaldo de Quirós Fernández, Tashinga E. Bapiro, Frances M. Richards, Duncan I. Jodrell
Journal: Cancer Research (2018)

Abstract Combination of cytotoxic therapy with emerging DNA damage response inhibitors (DDRi) has been limited by tolerability issues. However, the goal of most combination trials has been to administer DDRi with standard-of-care doses of chemotherapy. We hypothesized that mechanism-guided treatment scheduling could reduce the incidence of dose-limiting toxicities and enable tolerable multitherapeutic regimens. Integrative analyses of mathematical modeling and single-cell assays distinguished the synergy kinetics of WEE1 inhibitor (WEE1i) from CHEK1 inhibitor (CHK1i) by potency, spatiotemporal perturbation, and mitotic effects when combined with gemcitabine. These divergent properties collectively supported a triple-agent strategy, whereby a pulse of gemcitabine and CHK1i followed by WEE1i durably suppressed tumor cell growth. In xenografts, CHK1i exaggerated replication stress without mitotic CDK hyperactivation, enriching a geminin-positive subpopulation and intratumoral gemcitabine metabolite. Without overt toxicity, addition of WEE1i to low-dose gemcitabine and CHK1i was most effective in tumor control compared with single and double agents. Overall, our work provides quantitative insights into the mechanisms of DDRi chemosensitization, leading to the rational development of a tolerable multitherapeutic regimen. Significance: Multiple lines of mechanistic insight regarding DNA damage response inhibitors rationally guide the preclinical development of a tolerable multitherapeutic regimen. Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/11/3054/F1.large.jpg. Cancer Res; 78(11); 3054–66. ©2018 AACR.
Inhibitionof IL-1 signaling in hepatocytes retains insulin sensitivity and protects fromhepatocellular injury in nonalcoholic fatty liver disease
Authors: N. Gehrke, B. Straub, N. Hoevelmeyer, A. Waisman, K.Y. Ook, D. Schuppan, W. Marcus, P.R. Galle, J. Schattenberg
Journal: Journal of Hepatology (2018)
Recurrence and occurrence of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment for chronic hepatitis C in patients with advanced liver disease: Turkish multicenter early access program
Authors: R. Jdilman, M. Demir, M. Aladag, S. Kaymakoglu, C. Erol, B. Cavus, R. Iliaz, U.S. Akarca, S. Koklu, Y. Cakaloglu, M. Sahin, I. Koksal, M. Ozgenel, B. Toka, Z. Karasu, G. Ersoz, M. Kiyici, M. Akdogan, E.A.P. Turkey
Journal: Journal of Hepatology (2018)
Longitudinal outcomes of the application of non-selective beta-blockers in portal hypertension: Are low-dose non-selective beta-blockers effective?
Authors: S.H. Kang, M.Y. Kim, Y.O. Jang, M. Lee, B.G. Jun, T.-S. Kim, K.T. Suk, S.K. Baik
Journal: Journal of Hepatology (2018)
Re: Lee C. Zhao, Aaron C. Weinberg, Ziho Lee, et al. Robotic Ureteral Reconstruction Using Buccal Mucosa Grafts: A Multi-institutional Experience. Eur Urol 2018;73:419–26
Authors: Federico Gheza, Simone Crivellaro, Gian Luca Baiocchi
Journal: European Urology (2018)
Abstract 18368: Characterization of Myofibril Mechanics in Pediatric and Adult Patients With Idiopathic Dilated Cardiomyopathy
Authors: Mark Y Jeong, Ying Lin, Jennifer Mahaffey, Amrut A Ambardekar, Kika Sucharov, Brian Stuaffer, Shelley Miyamoto
Journal: Circulation (2016)

Introduction:  We studied mechanical properties of myofibrils from children and adults with and without HF to determine: 1) baseline myofibril characteristics, 2) differences between children and adults, 3) myofibril mechanics in the setting of HF.   Hypothesis:  Myofibril mechanics are different between adults and children.   Methods:  Myofibrils were obtained from pediatric and adult patients with idiopathic dilated cardiomyopathy (IDC) undergoing cardiac transplantation. Unused donor hearts were used as non-failing control (NF). Written informed consent was obtained and experiments were approved by the University of Colorado Institutional Review Board. Myofibril mechanical properties measured were: resting sarcomere length (SL, μm), resting and maximal tension (RT, T max , mN/mm 2 ); rate constant of tension development ( k  ACT , S -1 ); duration of linear relaxation ( t  LIN , mSec), rate constant of linear and exponential relaxation (linear and exponential  k  REL , S -1 ). Mechanical parameters ± SEM are shown.   Results:  Compared to NF adults, myofibrils from NF pediatric hearts had shorter SL (2.04±0.01 μm vs 2.10±0.01, P 2  vs 10.3±0.7 P t  LIN  (192.4±7.5 msec vs 153.4±3.7, P k  REL  (7.8±0.4 S -1  vs 15.4±0.8, P max ,  k  ACT , and linear  k  REL  were similar. In the adult group, IDC myofibrils showed slower  k  ACT  (0.45±0.02 S -1  vs 0.57±0.03, P k  REL  (11.9±0.7 S -1  vs 15.4+0.8, P max ,  t  LIN,  and linear  k  REL  were similar. In the pediatric group, IDC myofibrils developed lower T max  (35.3±2.5 mN/mm 2  vs 57.5+4.4, P t  LIN  (136.6±3.2 msec vs 202.3±8.9, P k  REL  (0.36±0.03 vs 0.57±0.06 P k  ACT  and exponential  k  REL  were similar.   Conclusions:  NF myofibrils from children have shorter resting SL and slower relaxation kinetics than NF adults. While myofibrils from adult IDC display slower activation and exponential relaxation kinetics, children with IDC display altered linear relaxation kinetics and reduced tension generation. These results show that myofibrils from children have fundamental differences in mechanical characteristics at baseline and in response to heart failure.
The clinical significance and synchronous polyp burden of large (≥ 20 mm) sessile serrated polyps in patients without serrated polyposis syndrome
Authors: Lobke Desomer, David J. Tate, Mahesh Jayanna, Maria Pellise, Halim Awadie, Nicholas G. Burgess, Duncan McLeod, Hema Mahajan, Eric Y. T. Lee, Stephen J. Williams, Michael J. Bourke
Journal: Endoscopy (2018)

Sessile serrated polyps (SSPs) are important precursors of colorectal carcinoma and interval cancer. Large SSPs (≥ 20 mm) outside the definition of serrated polyposis syndrome (SPS) have not been studied in comparison with SPS. We aimed to describe the characteristics of patients with large SSPs in this context.Patients with at least one SSP (≥ 20 mm) were eligible. Data from three consecutive colonoscopies were used to compare clinical and endoscopic characteristics in three patient groups: SPS, a solitary large SSP, and patients with at least two SSPs without fulfilling the criteria for SPS (oligo-SSP). Data on the diagnostic colonoscopy were collected retrospectively, whereas the remaining data was collected prospectively.67/146 patients (45.9 %) had SPS, 53/146 (36.3 %) had a solitary SSP, and 26/146 (17.8 %) were categorized as oligo-SSP. Personal (16.4 %, 9.4 %, and 11.5 %, respectively) and family (17.9 %, 17.0 %, and 23.1 %, respectively) history of colorectal carcinoma did not differ significantly between groups. Polyp burden was greater in SPS compared with solitary SSP but was not different from oligo-SSP (advanced adenomas: SPS 32.8 % vs. solitary SSP 9.4 % [P = 0.002] vs. oligo-SSP 34.6 % [P = 0.87]; ≥ 10 conventional adenomas: 11.9 % vs. 0 % [P = 0.01] vs. 3.8 % [P = 0.44], respectively). Dysplasia in large SSPs was frequent in all groups (41.1 % overall). SPS was recognized by referring endoscopists in only 9.0 % of cases.Patients with oligo-SSPs have similar synchronous polyp burden and clinical characteristics as patients with SPS and may require similar surveillance. Modification of the criteria for the diagnosis of SPS to include this group seems warranted. Patients with a solitary SSP have a lower risk of synchronous polyps, including advanced adenomas. Larger studies are warranted to determine whether these patients may return to standard surveillance following complete examination and clearance of the colon.